Litcius/Paper detail

Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial

Eleonora F. Spinazzi, Michael Argenziano, Pavan S. Upadhyayula, Matei A. Banu, Justin A. Neira, Dominique Higgins, Peter Wu, Brianna Pereira, Aayushi Mahajan, Nelson Humala, Osama Al‐Dalahmah, Wenting Zhao, Akshay Save, Brian Gill, Deborah Boyett, Tamara Marie, Julia Furnari, Tejaswi Sudhakar, Sylwia A. Stopka, Michael S. Regan, Vanessa V. Catania, Laura Good, Stergios Zacharoulis, Meenu Behl, Petros Petridis, Sachin Jambawalikar, Akiva Mintz, Angela Lignelli, Nathalie Y.R. Agar, Peter A. Sims, Mary Welch, Andrew B. Lassman, Fábio M. Iwamoto, Randy S. D’Amico, Jack Grinband, Peter Canoll, Jeffrey N. Bruce

2022The Lancet Oncology88 citationsDOIOpen Access PDF

Topics & Concepts

MedicineTopotecanSurgeryGliomaAdverse effectClinical trialChemotherapyRegimenPhases of clinical researchClinical endpointOncologyInternal medicineCancer researchGlioma Diagnosis and TreatmentCerebrospinal fluid and hydrocephalusNanoparticle-Based Drug Delivery
Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial | Litcius